Proscia's new survey reveals that approximately 70% of life science organizations have invested in digital pathology to advance drug research and development. Over half of these organizations still use legacy software systems, primarily for basic image viewing, despite the growing adoption of artificial intelligence (AI) to accelerate the introduction of breakthrough therapeutics. The survey also highlights an intensifying need for an enterprise pathology platform that incorporates a broad portfolio of AI applications into routine operations. Executives see digital pathology as a solution to R&D’s biggest challenges, with 80% seeing it as a means of overcoming lengthy timelines and 68% viewing the technology as a way to cut costs. Furthermore, 82% of respondents that use digital pathology have begun implementing AI, while all other current users surveyed plan to adopt AI.
Keywords: Proscia, survey, digital pathology, drug research and development, legacy software systems.
The "2023 Life Sciences Digital Pathology Adoption Survey" conducted by Atheneum on behalf of Proscia found that more than two-thirds of life sciences organizations have invested in digital pathology for drug research and development purposes. Despite this investment, over half still rely on outdated legacy software systems for basic image viewing. There is now a growing need for modern software platforms incorporating AI applications to